CD80 (B7.1) expression. A standard two-dose-escalation phase I clinical trial was conducted with 12 metastatic melanoma patients, using a recombinant VV expressing B7.1 (rV-B7.1) [200]. This evidence concerns the gene CD80 and metastatic melanoma.